Tuberculin Skin Test Reliability and Preferred Use of IGRAs in BCG‑Vaccinated Individuals

Validity of TST After BCG Vaccination

Interpretation Thresholds for TST in BCG‑Vaccinated Persons

Preference for Interferon‑Gamma Release Assays (IGRAs)

Practical Testing Algorithm for BCG‑Vaccinated Individuals

Common Pitfalls and Boosting Effects

All facts are drawn from CDC/MMWR recommendations and peer‑reviewed guidelines; the evidence is considered strong (public health guideline level) where explicitly recommended.

Tuberculosis Screening in BCG-Vaccinated Individuals

Key Principles

• The Centers for Disease Control and Prevention recommends that prior BCG vaccination should not prevent tuberculin skin testing, and positive reactions (≥10 mm induration) should be interpreted as indicating true M. tuberculosis infection and managed accordingly, especially in individuals from high TB-prevalence countries or with other risk factors 6, 7, 8
• The American Thoracic Society suggests that tuberculin skin testing is not contraindicated in BCG-vaccinated persons, and results should be used to support or exclude the diagnosis of M. tuberculosis infection 6, 9

Interpretation Thresholds

• The Centers for Disease Control and Prevention recommends using ≥10 mm induration as positive in BCG-vaccinated individuals who are contacts of someone with infectious TB, were born in or have resided in a high TB-prevalence country, or have continuous exposure to high-prevalence populations 6, 9
• The American Thoracic Society suggests using ≥5 mm induration as positive in BCG-vaccinated individuals who are HIV-infected, recent close contacts of an active TB case, or have fibrotic changes on chest radiograph consistent with prior TB 6, 7, 8

Rationale for Not Attributing Positive Tests to BCG

• The American Journal of Respiratory and Critical Care Medicine notes that several evidence-based reasons support treating positive reactions as true infection rather than vaccine effect, including tuberculin test conversion rates after BCG vaccination, mean reaction size among BCG recipients, and tuberculin sensitivity from BCG tending to wane over time after vaccination 7, 8

Alternative Testing

• The Centers for Disease Control and Prevention recommends that Interferon-Gamma Release Assays (IGRAs) are preferred over TST in BCG-vaccinated individuals because they eliminate false-positive results caused by BCG cross-reaction, have higher specificity, and measure interferon-gamma release to M. tuberculosis-specific antigens not found in BCG vaccines 10

Two-Step Testing

• The Centers for Disease Control and Prevention suggests that two-step baseline testing should be performed to identify boosted reactions and prevent misclassification as new infections in BCG-vaccinated individuals entering serial testing programs, with an initial TST at baseline and a repeat TST 1-3 weeks later if negative 11, 12

Follow-Up After Positive Test

• The American Thoracic Society recommends performing chest radiograph to exclude active TB disease, and if normal, treating for latent TB infection according to standard guidelines, and evaluating family members and close contacts for TB infection 6, 9, 10